# Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

> **NCT03626376** · PHASE4 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Herpes Simplex Virus Keratitis

## Interventions

- **DRUG:** oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily
- **DRUG:** oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops

## Key facts

- **NCT ID:** NCT03626376
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-10
- **Primary completion:** 2021-03-02
- **Final completion:** 2022-03-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to enroll participants
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03626376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03626376, "Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03626376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*